Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference
Date:9/21/2010

o certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug–delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... News) -- Medicare should cover low-dose computed tomography lung ... disease, a coalition of more than 60 patient and ... Lung Cancer Alliance, the Society of Thoracic Surgeons, the ... the American Society of Clinical Oncology, made its point ... for Medicare & Medicaid Services (CMS). Such screening ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Benedict XVI’s intention of soliciting a report on the acceptability ... //in exceptional cases, such as, in the event of either ... life within the precincts of marriage. ,Experts have commended ... issue such as this, while also agreeing that such an ...
... on its last lap of seeking enrollment from drug companies, and ... with three major insurance players. ,United Health Group seems to ... endorsers and a financial agreement with them to support the company. ... Medicare. ,80 companies have been in the fray with ...
... mother’s heart disease rather than the father’s tend to pose ... history of coronary disease//. ,The results of the ... American Journal of Preventive Medicine. This could help to better ... coronary problems as well as show early signs of the ...
... getting known for its severe dearth of general practitioners, further ... in the throes of a severe GP crisis. ,The ... the current trend of Doctors, gravitating to specialist sectors, which ... GP sector lean and totally understaffed. ,Dr Catherine ...
... been accused of the murder of three family members whose ... court appearance. // ,The victims were Marc Richardson, ... and a funeral visitation has been planned for them today ... Toussaint Church in Sudbury. ,The girl's boyfriend, an ...
... The World Health Organization WHO has recently released its ... // The United Nations health agency found that ... they are adequately nurtured and they claimed that the ... ,The W.H.O. says it now has scientific evidence ...
Cached Medicine News:Health News:Risk of Heart Disease Greater from Mom than Dad 2Health News:An International Growth Standard For Childs Releases By WHO 2
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: